Findings

What do systematic reviews say?

1,495 questions · 1,554 findings · 140 reviews · Heart

Sort:Best matchNewestHighest certainty Download CSV

No studies found 272 · 17.5%GRADE not reported 44 · 2.8%Very low 329 · 21.2%Low 464 · 29.9%Moderate 319 · 20.5%High 126 · 8.1%

Does treatment guided by serial BNP or NT‐proBNP monitoring improve outcomes vs treatment guided by clinical assessment alone?

Quality of life (MLHFQ): from 0 to 105 · patients with heart failure

1 finding from 1 review

B‐type natriuretic peptide‐guided treatment for heart failure 2016 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1812 participants
Very low

Carvedilol vs placebo

All‐cause mortality · heart failure in patients with Chagas cardiomyopathy

It is very uncertain whether carvedilol changes all‐cause mortality compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
RR 0.69 [0.12, 3.88]
2 studies · 69 participants
Very low

Rosuvastatin vs placebo

Time to heart decompensation · chronic heart failure in Chagas cardiomyopathy patients

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
GRADE not reported

Rosuvastatin vs placebo

Disease‐free period at 30, 60 and 90 days · chronic heart failure in Chagas cardiomyopathy patients

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
GRADE not reported

Rosuvastatin vs placebo

Quality of life · chronic heart failure in Chagas cardiomyopathy patients

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Very low

Rosuvastatin vs placebo

Adverse events · chronic heart failure in Chagas cardiomyopathy patients

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
GRADE not reported

Rosuvastatin vs placebo

Hospital readmissions (heart failure‐ or adverse event‐related) · chronic heart failure in Chagas cardiomyopathy patients

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
GRADE not reported

Carvedilol vs placebo

Cardiac mortality · heart failure in patients with Chagas cardiomyopathy

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 69 participants
GRADE not reported

Carvedilol vs placebo

Time to heart decompensation · heart failure in patients with Chagas cardiomyopathy

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 69 participants
GRADE not reported

Carvedilol vs placebo

Disease‐free period at 30, 60 and 90 days · heart failure in patients with Chagas cardiomyopathy

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 69 participants
GRADE not reported

Carvedilol vs placebo

Overall survival · heart failure in patients with Chagas cardiomyopathy

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Very low

Carvedilol vs placebo

Quality of life · heart failure in patients with Chagas cardiomyopathy

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Carvedilol vs placebo

Adverse events · heart failure in patients with Chagas cardiomyopathy

It is very uncertain whether carvedilol changes adverse events compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
RR 0.92 [0.67, 1.27]
1 study · 30 participants
Very low

Rosuvastatin vs placebo

All‐cause mortality · chronic heart failure in Chagas cardiomyopathy patients

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
GRADE not reported

Rosuvastatin vs placebo

Cardiac mortality · chronic heart failure in Chagas cardiomyopathy patients

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
GRADE not reported

Intervention not reported

Cardiovascular mortality · people with hyperlipidaemia

1 finding from 1 review

Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Intervention not reported

Cardiovacular morbidity · people with hyperlipidaemia

1 finding from 1 review

Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Intervention not reported

At least 1 adverse event · people with hyperlipidaemia

The intervention showed no clear difference in at least 1 adverse event (low certainty).

1 finding from 1 review

Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia 2016 · Cochrane Headline outcomes only
OR 0.71 [0.44, 1.15]
5 studies · 556 participants
Low

Intervention not reported

Total Cholesterol (mg/dL) · people with hyperlipidaemia

1 finding from 1 review

Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 514 participants
Low

Intervention not reported

LDL‐C (mg/dL) · people with hyperlipidaemia

1 finding from 1 review

Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 473 participants
Low